A detailed history of Flossbach Von Storch Ag transactions in Bio N Tech Se stock. As of the latest transaction made, Flossbach Von Storch Ag holds 4,359,607 shares of BNTX stock, worth $498 Million. This represents 2.05% of its overall portfolio holdings.

Number of Shares
4,359,607
Previous 4,379,483 0.45%
Holding current value
$498 Million
Previous $352 Million 47.13%
% of portfolio
2.05%
Previous 1.49%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$78.36 - $124.66 $1.56 Million - $2.48 Million
-19,876 Reduced 0.45%
4,359,607 $518 Million
Q2 2024

Aug 02, 2024

BUY
$80.36 - $102.87 $73.2 Million - $93.7 Million
910,497 Added 26.25%
4,379,483 $352 Million
Q1 2024

May 06, 2024

SELL
$88.96 - $112.35 $7.09 Million - $8.95 Million
-79,674 Reduced 2.25%
3,468,986 $320 Million
Q4 2023

Jan 31, 2024

BUY
$90.91 - $112.75 $3.22 Million - $4 Million
35,445 Added 1.01%
3,548,660 $375 Million
Q3 2023

Oct 27, 2023

BUY
$98.5 - $125.08 $7.04 Million - $8.94 Million
71,468 Added 2.08%
3,513,215 $382 Million
Q2 2023

Aug 02, 2023

BUY
$102.58 - $129.66 $965,585 - $1.22 Million
9,413 Added 0.27%
3,441,747 $371 Million
Q1 2023

May 03, 2023

BUY
$122.57 - $153.67 $18.3 Million - $23 Million
149,611 Added 4.56%
3,432,334 $428 Million
Q4 2022

Feb 06, 2023

SELL
$118.43 - $186.05 $9.69 Million - $15.2 Million
-81,841 Reduced 2.43%
3,282,723 $493 Million
Q3 2022

Nov 14, 2022

BUY
$127.65 - $183.11 $38.2 Million - $54.8 Million
299,414 Added 9.77%
3,364,564 $454 Million
Q2 2022

Aug 10, 2022

BUY
$123.25 - $186.24 $141 Million - $213 Million
1,145,061 Added 59.64%
3,065,150 $457 Million
Q1 2022

May 11, 2022

BUY
$126.25 - $231.85 $242 Million - $445 Million
1,920,089 New
1,920,089 $327 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.7B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Flossbach Von Storch Ag Portfolio

Follow Flossbach Von Storch Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flossbach Von Storch Ag, based on Form 13F filings with the SEC.

News

Stay updated on Flossbach Von Storch Ag with notifications on news.